

change: Susceptibility Panel Updates for Gram Negative Organisms

EFFECTIVE: June 2021

Breakpoint changes and additional combination antimicrobials

The Microbiology Lab will be transitioning to an updated susceptibility panel for gram negative organisms. Updated susceptibility panel has the following breakpoint changes and additional antimicrobial combinations.

Breakpoint changes:

Ciprofloxacin

Levofloxacin

Old breakpoints	<i>Enterobacteriales</i>			<i>Pseudomonas aeruginosa</i>		
	S	I	R	S	I	R
Ciprofloxacin	<=1	2	>=4	<=1	2	>=4
Levofloxacin	<=2	4	>=8	<=2	4	>=8

New breakpoints	<i>Enterobacteriales</i>			<i>Pseudomonas aeruginosa</i>		
	S	I	R	S	I	R
Ciprofloxacin	<=0.25	0.5	>=1	<=0.5	1	>=2
Levofloxacin	<=0.5	1	>=2	<=1	2	>=4

New beta-lactam combination agents:

Ceftazidime – avibactam (CZA)

Ceftolozane – tazobactam (C/T)

Meropenem – vaborbactam (MEV)

Above mentioned combination agents will only be reported if indicated, following current antimicrobial susceptibility protocol reflex testing criteria.

Reference:

CLSI M100-Ed31 Performance Standards for Antimicrobial Susceptibility Testing

If you have questions or need additional information, please contact Laboratory Client Services at (916) 734-7373 or email hs-patholclientserv@ucdavis.edu